Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.

Kohlmann A, Nadarajah N, Alpermann T, Grossmann V, Schindela S, Dicker F, Roller A, Kern W, Haferlach C, Schnittger S, Haferlach T.

Leukemia. 2014 Jan;28(1):129-37. doi: 10.1038/leu.2013.239. Epub 2013 Aug 20.

PMID:
23958918
2.

RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.

Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK.

Haematologica. 2012 Dec;97(12):1909-15. doi: 10.3324/haematol.2012.064667. Epub 2012 Jun 11.

3.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2012 Sep 1;30(25):3109-18. doi: 10.1200/JCO.2011.40.6652. Epub 2012 Jul 2.

4.

RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation.

Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL, Shih LY.

Leukemia. 2009 Aug;23(8):1426-31. doi: 10.1038/leu.2009.48. Epub 2009 Mar 12.

PMID:
19282830
5.

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.

Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Lin LI, Tien HF.

Blood. 2009 Dec 17;114(26):5352-61. doi: 10.1182/blood-2009-05-223784. Epub 2009 Oct 6.

7.

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.

Duployez N, Nibourel O, Marceau-Renaut A, Willekens C, Helevaut N, Caillault A, Villenet C, Celli-Lebras K, Boissel N, Jourdan E, Dombret H, Figeac M, Preudhomme C, Renneville A.

Am J Hematol. 2014 Jun;89(6):610-5. doi: 10.1002/ajh.23696. Epub 2014 Mar 8.

8.

Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia.

Grossmann V, Kern W, Harbich S, Alpermann T, Jeromin S, Schnittger S, Haferlach C, Haferlach T, Kohlmann A.

Haematologica. 2011 Dec;96(12):1874-7. doi: 10.3324/haematol.2011.043919. Epub 2011 Aug 9.

9.

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.

Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, Ifrah N, Dombret H, Jourdan E, Preudhomme C, Boissel N; French AML Intergroup..

Haematologica. 2016 Mar;101(3):328-35. doi: 10.3324/haematol.2015.131946. Epub 2015 Dec 3.

10.

Frequent coexistence of RAS mutations in RUNX1-mutated acute myeloid leukemia in Arab Asian children.

Al-Kzayer LF, Sakashita K, Al-Jadiry MF, Al-Hadad SA, Uyen le TN, Liu T, Matsuda K, Abdulkadhim JM, Al-Shujairi TA, Matti ZI, Hasan JG, Al-Abdullah HM, Inoshita T, Kamata M, Sughayer MA, Madanat FF, Koike K.

Pediatr Blood Cancer. 2014 Nov;61(11):1980-5. doi: 10.1002/pbc.25151. Epub 2014 Jul 25.

PMID:
25066867
11.

Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.

Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ.

Chin J Cancer. 2016 May 19;35:46. doi: 10.1186/s40880-016-0110-6.

12.

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.

Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K.

Haematologica. 2015 Mar;100(3):324-30. doi: 10.3324/haematol.2014.114157. Epub 2015 Jan 16.

13.

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing.

Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D.

Mod Pathol. 2014 Nov;27(11):1438-46. doi: 10.1038/modpathol.2014.57. Epub 2014 Apr 18.

14.

Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis.

Skokowa J, Steinemann D, Katsman-Kuipers JE, Zeidler C, Klimenkova O, Klimiankou M, Unalan M, Kandabarau S, Makaryan V, Beekman R, Behrens K, Stocking C, Obenauer J, Schnittger S, Kohlmann A, Valkhof MG, Hoogenboezem R, Göhring G, Reinhardt D, Schlegelberger B, Stanulla M, Vandenberghe P, Donadieu J, Zwaan CM, Touw IP, van den Heuvel-Eibrink MM, Dale DC, Welte K.

Blood. 2014 Apr 3;123(14):2229-37. doi: 10.1182/blood-2013-11-538025. Epub 2014 Feb 12.

15.

In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification.

Wang Y, Wu DP, Liu QF, Qin YZ, Wang JB, Xu LP, Liu YR, Zhu HH, Chen J, Dai M, Huang XJ.

Blood. 2014 Sep 18;124(12):1880-6.

16.

Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.

Silva FP, Almeida I, Morolli B, Brouwer-Mandema G, Wessels H, Vossen R, Vrieling H, Marijt EW, Valk PJ, Kluin-Nelemans HC, Sperr WR, Ludwig WD, Giphart-Gassler M.

Haematologica. 2009 Nov;94(11):1546-54. doi: 10.3324/haematol.2009.009324. Epub 2009 Sep 22.

17.

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.

Hoyos M, Nomdedeu JF, Esteve J, Duarte R, Ribera JM, Llorente A, Escoda L, Bueno J, Tormo M, Gallardo D, de Llano MP, Martí JM, Aventín A, Mangues R, Brunet S, Sierra J.

Eur J Haematol. 2013 Sep;91(3):209-18. doi: 10.1111/ejh.12130. Epub 2013 Jul 25.

PMID:
23646898
18.

Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status.

Silva FP, Swagemakers SM, Erpelinck-Verschueren C, Wouters BJ, Delwel R, Vrieling H, van der Spek P, Valk PJ, Giphart-Gassler M.

Blood. 2009 Oct 1;114(14):3001-7. doi: 10.1182/blood-2009-03-211334. Epub 2009 Aug 7.

19.

Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencing.

Malmberg EB, Ståhlman S, Rehammar A, Samuelsson T, Alm SJ, Kristiansson E, Abrahamsson J, Garelius H, Pettersson L, Ehinger M, Palmqvist L, Fogelstrand L.

Eur J Haematol. 2017 Jan;98(1):26-37. doi: 10.1111/ejh.12780. Epub 2016 Jun 8.

PMID:
27197529
20.

Repression of vascular endothelial growth factor expression by the runt-related transcription factor 1 in acute myeloid leukemia.

Ter Elst A, Ma B, Scherpen FJ, de Jonge HJ, Douwes J, Wierenga AT, Schuringa JJ, Kamps WA, de Bont ES.

Cancer Res. 2011 Apr 1;71(7):2761-71. doi: 10.1158/0008-5472.CAN-10-0402. Epub 2011 Mar 29.

Supplemental Content

Support Center